Smart Search





Results for NEUROPROTEC... > Neuroprotective Agents: Implications for Parkinson's Disease Treatment

Neuroprotective Agents: Implications for Parkinson's Disease Treatment

MENU

By

Algantri, KR (Algantri, Khaled Ramadan); Mohamed, W (Mohamed,

Wael); Nasir, MHM (Nasir, Mohd Hamzah Mohd); Nahas, ARMF

(Nahas, Abdul Rahman Mahmoud Fata)

Source

CURRENT ALZHEIMER RESEARCH

DOI: 10.2174/0115672050368080250529075006

Early Access

JUL 2025

Indexed

2025-10-13

Document Type

Review; Early Access

Abstract

Parkinson's disease (PD) is a multifaceted neurodegenerative condition marked by the progressive loss of dopaminergic neurons, leading to impairments in movement and cognition. This research offers an in-depth examination of the pathophysiological pathways associated with PD, emphasising the roles of oxidative stress, mitochondrial dysfunction, and neuroinflammation. The study examines the interaction between genetic and environmental factors in the development of PD, highlighting the significance of oxidative stress, mitochondrial dysfunction, and excitotoxicity in the degeneration of dopaminergic neurons. It also looks into the impact of neuroinflammation and microglial activation on the causes of PD. Despite considerable progress in research, there remains a lack of effective treatments that can modify the course of the disease, highlighting the pressing need for new therapeutic

approaches that address mitochondrial malfunction, oxidative





stress, and neuroinflammation. This study assesses the neuroprotective efficacy of various substances, notably natural agents like resveratrol, curcumin, ginsenoside, and melatonin, for managing PD. Although these natural chemicals show promise, further robust clinical trials are needed to confirm their effectiveness and safety, as well as to investigate their potential incorporation into conventional PD treatment.

Keywords

Author Keywords: Neuroprotective agents; Parkinson's disease (PD); reactive oxygen species (ROS); substantia nigra pars compacta (SNpc); bradykinesia; mitochondrial dysfunction

Keywords Plus: DOPAMINERGIC-NEURONS; PHOENIX-DACTYLIFERA; DIETARY SUPPLEMENTATION; CLINICAL PROGRESSION; ANTIOXIDANT ACTIVITY; COMBINATION THERAPY; NEUROTROPHIC FACTOR; OXIDATIVE STRESS; VITAMIN-E; MODEL

Addresses

- ¹ Widad Univ Coll, Fac Med, Med Educ Unit, Bandar Indera Mahkota BIM Point, Kuantan 25200, Pahang, Malaysia
- ² Int Islamic Univ Malaysia, Dept Basic Med Sci, Kuantan 25200, Pahang, Malaysia
- ³ Menoufia Univ, Menoufia Med Sch, Clin Pharmacol Dept, Menoufia, Egypt
- ⁴ Int Islamic Univ Malaysia, Kulliyyah Sci, Dept Biotechnol, Bandar Indera Mahkota 25200, Kuantan, Malaysia
- ⁵ Int Islamic Univ Malaysia, Dept Pharm Practice, Kulliyyah Pharm, Kuantan 25200, Pahang, Malaysia

Categories/ Classification Research Areas: Neurosciences & Neurology

Web of Science Categories Clinical Neurology; Neurosciences

Language English

Accession Number WOS:001588054000001

ISSN 1567-2050

eISSN 1875-5828

See fewer data fields

Citation Network

Use in Web of Science

In Web of Science Core Collection

1

Citation

174

Cited References

 \circ

Last 180 Days Since 2013

This record is from:

Web of Science Core Collection

 Science Citation Index Expanded (SCI-EXPANDED)

Suggest a correction

If you would like to improve the quality of the data in this record, please <u>Suggest a correction</u>

Clarivate

© 2025 Clarivate. All rights reserved.

Legal Training
Center Portal
Privacy Product
Statement Support
Copyright Newsletter
Notice

Cookie Accessibility
Policy Help
Manage Terms of
cookie Use
preferences
Data
Correction

Follow Us



